Filter Results :

Your search for Therapies returned 73 reports

Sort by


Natural Killer Cells Therapies- Competitive Landscape,Technology and Pipeline Analysis, 2017

01 Jun 2017  |  Published by:  DelveInsight
“Natural Killer Cells Therapies- Competitive Landscape, Technology and Pipeline Analysis, 2017”, emphasizes on the currently active NK cell therapy products and NK cell augmenters in research and development.  The report covers 20+ companies, which are active in this field with 40+ products and...

$ 2,450.00

Read More

Vital Therapies Inc (VTL) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

18 May 2017  |  Published by:  GlobalData
SummaryVital Therapies Inc (Vital Therapies) is a bio therapeutic company that focuses on the development of cell-based therapy treatment for liver failure. The company’s clinical trials include VTI-206, VTI-208, VTI-210, VTI-201, VTIC-301, and VTI-212. Its product ELAD is a human cell based liver s...

$ 250.00

Read More

Vital Therapies Inc (VTL) - Financial and Strategic SWOT Analysis Review

15 May 2017  |  Published by:  GlobalData
SummaryVital Therapies Inc (Vital Therapies) is a bio therapeutic company that focuses on the development of cell-based therapy treatment for liver failure. The company’s clinical trials include VTI-206, VTI-208, VTI-210, VTI-201, VTIC-301, and VTI-212. Its product ELAD is a human cell based liver s...

$ 300.00

Read More

Frontier Pharma: First-in-Class Innovation in Hematological Cancers - Cytokine Signaling and Kinase Targeted Immunotherapies Dominate a Large and Highly Versatile Pipeline

03 May 2017  |  Published by:  GBI Research
SummaryThe American Cancer Society (ACS) predicts that in 2017 there will be almost 173,000 new cases of leukemia, lymphoma and myeloma, with lymphomas the most prevalent. Due to a degree of crossover between hematological malignancies in terms of their underlying pathophysiology, it is not uncommon...

$ 6,995.00

Read More

Frontier Pharma: Alzheimer's Disease and Associated Indications - Exceptional Level of First-in-Class Innovation within AD, and Diverse Range of Therapies in Development for Disorders Such as Anxiety and Depression

01 May 2017  |  Published by:  GBI Research
SummaryAlzheimer’s disease (AD), the most common form of dementia, is a progressive, neurodegenerative and currently incurable disease characterized by loss of memory and other mental abilities. It has a devastating impact on independence and quality of life, with patients requiring full-time care i...

$ 6,995.00

Read More

Intra-Cellular Therapies Inc (ITCI) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

26 Apr 2017  |  Published by:  GlobalData
SummaryIntra-Cellular Therapies Inc (ITI) is a biopharmaceutical company that concentrates on the discovery and development of small molecule drugs to treat neuropsychiatric and neurologic disorders. The companys lead product candidate, ITI-007, which is intended for the treatment of schizophrenia, ...

$ 250.00

Read More

Biotie Therapies Corp (BTH1V) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

20 Apr 2017  |  Published by:  GlobalData
SummaryBiotie Therapies Corp (Biotie) is a pharmaceutical company that discovers and develops new medicines for the treatment of various diseases. The company offers products for use in the treatment of neurodegenerative and psychiatric disorders such as parkinson's disease, alzheimer's disease, pri...

$ 250.00

Read More

BioRestorative Therapies Inc (BRTX) - Pharmaceuticals & Healthcare - Deals and Alliances Profile

20 Apr 2017  |  Published by:  GlobalData
SummaryBioRestorative Therapies Inc (BRT), formerly Stem Cell Assurance, Inc. is a biotechnology company that develops products and therapies using cell and tissue protocols. The company performs stem cell programs which include brtxDISC and ThermoStem. brtxDISC,a lead therapeutic product, is design...

$ 250.00

Read More

Vital Therapies Inc (VTL) - Medical Equipment - Deals and Alliances Profile

18 Apr 2017  |  Published by:  GlobalData
SummaryVital Therapies Inc (Vital Therapies) is a bio therapeutic company that focuses on the development of cell-based therapy treatment for liver failure. The company's clinical trials include VTI-206, VTI-208, VTI-210, VTI-201, VTIC-301, and VTI-212. Its product ELAD is a human cell based liver s...

$ 250.00

Read More

Advanced Inhalation Therapies (AIT) Ltd - Pharmaceuticals & Healthcare - Deals and Alliances Profile

18 Apr 2017  |  Published by:  GlobalData
SummaryAdvanced Inhalation Therapies (AIT) Ltd (AIT) focuses on the development and commercialization of nitric oxide (NO) based formulations for respiratory or infectious diseases. The company's pipeline product portfolio comprises NOxBR, NOxCF, NOxCOPD and NOxSYS. Its NOxBS is a proprietary delive...

$ 250.00

Read More

Advanced Catheter Therapies Inc - Medical Equipment - Deals and Alliances Profile

06 Apr 2017  |  Published by:  GlobalData
SummaryAdvanced Catheter Therapies Inc (ACT) is a medical device company that offers novel catheter technologies targeting vascular disease such as inflammation, thrombosis, occlusions and restenosis. The company is developing a device for restenosis and catheters for endovascular debulking. It offe...

$ 250.00

Read More

Rheumatoid Arthritis Therapeutics in South-East Asia Markets to 2022 - Novel JAK and IL-6 Receptor Inhibitors to Stimulate Moderate Growth Despite Launch of Biosimilars of Blockbuster Anti-TNFs Breast Cancer Therapeutics in Southeast Asia Markets to 2022 - Increasing Prevalence and Usage of Premium Targeted Therapies to Drive the Market

01 Apr 2017  |  Published by:  GBI Research
SummaryRheumatoid Arthritis (RA) is a chronic, progressive and currently incurable autoimmune disease that primarily affects the joints. It is characterized by synovial inflammation and gradual bone erosion over many years. Disease progression results in stiffness and pain, especially in the hands a...

$ 4,995.00

Read More

Breast Cancer Therapeutics in Southeast Asia Markets to 2022 - Increasing Prevalence and Usage of Premium Targeted Therapies to Drive the Market

01 Apr 2017  |  Published by:  GBI Research
SummaryBreast cancer is a malignant neoplasm that begins in the breast tissue. Most breast cancers are invasive cancers that have grown beyond the ducts or lobules and can metastasize to other parts of the body through the bloodstream and the lymphatic system. Broadly, patients can be segmented into...

$ 4,995.00

Read More

Antibacterial Therapies Drug Development Pipeline Review, 2017

22 Mar 2017  |  Published by:  GBI Research
SummaryThe antibacterial drug market covers the drugs used in the prophylaxis and treatment of bacterial infections. With a growing global concern over antimicrobial resistance and its progressive growth, there is a pronounced need for innovation within this market.There are over 1400 products in ac...

$ 3,995.00

Read More

Non-Small Cell Lung Cancer Therapeutics in Asia-Pacific Markets to 2023 - Launch of Premium Targeted Therapies and Increasing Prevalence to Drive the Market

09 Mar 2017  |  Published by:  GBI Research
SummaryNon-Small Cell Lung Cancer (NSCLC) is the most common cancer and the leading cause of cancer-related mortality globally. There were more than 1.8 million newly diagnosed lung cancer cases in 2012, accounting for 13% of the total number of cancer cases. This figure has been gradually rising wi...

$ 4,995.00

Read More
Total 73 records.